A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty

What Was Tested

In this not phased trial, researchers set out to test Methylene blue (non-peptide stack partner).

In recent years, the widespread application of ultrasound has achieved good clinical results in iliac fascia block for postoperative analgesia in THA.

It had two arms (groups): one (no intervention) and one (experimental).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 90 actual participants took part.

It was open to people of any sex aged from 65 years up to 85 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Hip replacement surgery is indicated. ASA Class II - Class III. No history of analgesic or local anesthetic allergy. No history of alcohol abuse or narcotic drug abuse. Patients and their families have given informed consent and signed the informed consent form.

The full record lists 5 inclusion and 9 exclusion criteria; among the exclusions: patient or family refusal to participate in the study; severe coagulation abnormalities; local anesthetic allergy.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and outcomes assessor.

It started in 2023-06-20 with completion listed for 2024-02-28.

It ran at 1 site in China.

Its stated primary purpose is other.

What Was Measured

The main thing measured (primary outcome): Visual Analogue Scale（VAS）.

It also tracked 9 secondary outcomes, for example Hypersensitive C-reactive Protein, Procalcitonin, Neutrophil Lymphocyte Ratio, Mean Arterial Pressure, Heart Rate and Duration of Surgery.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Methylene blue (non-peptide stack partner) in 90 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.